Adalimumab for Rheumatoid Arthritis
- 19 Downloads
Third-party payors and national health systems require evidence that new medications for rheumatoid arthritis are cost effective. To determine cost effectiveness, one must consider the cost of a given therapy versus the long-term cost of the disease, with and without therapy. The direct and indirect costs of rheumatoid arthritis over the course of the disease, including the considerable costs related to hospitalization and disability, have been quantified. Resource utilization and treatment costs are high for patients with rheumatoid arthritis, and there is a strong link between functional disability and direct cost of care.
Traditional disease-modifying antirheumatic drugs (DMARDs) [such as methotrexate and gold] have limited long-term effects in improving lives and avoiding costs for patients with rheumatoid arthritis. Tumor necrosis factor (TNF) antagonists, the newest class of rheumatoid arthritis drug therapies, significantly improve patient outcomes, including reducing the signs and symptoms of rheumatoid arthritis, improving physical function and health-related quality of life, and inhibiting radiographie damage. Failing to treat rheumatoid arthritis effectively is very costly; effective treatment includes early, aggressive therapy. As a result, the National Health Service in the UK, other societal decision-makers, and third-party payors have recommended the use of TNF antagonists, in many instances, for the treatment of rheumatoid arthritis.
The TNF antagonists — infliximab, etanercept, and the most recently approved, adalimumab — address the limitations of traditional DMARDs, thus setting a new therapeutic standard for rheumatoid arthritis. Data from three key studies (Anti-TNF Research Program of the Monoclonal Antibody Adalimumab in Rheumatoid Arthritis, DE019 and DE011) indicate that adalimumab provides a rapid, sustainable, predictable, and significantly greater reduction in the signs and symptoms of rheumatoid arthritis than traditional DMARDs. Adalimumab yields significantly less structural joint damage as measured by the total Sharp scores and scores on its two major components: joint erosions and joint space narrowing. It also improves physical function (as measured by the Health Assessment Questionnaire Disability Index) and health utility (as measured by the Health Utilities Index Mark 3).
In conclusion, rheumatoid arthritis and other musculoskeletal diseases are costly, but an upfront investment in highly effective therapies may provide long-term cost savings compared with traditional therapies. The immediate, out-of-pocket costs of TNF antagonists are greater than traditional DMARDs, but with the potential to significantly improve response rates, inhibit structural joint damage, and improve disability and health utility, TNF antagonists have the potential to be more cost effective over the long run. TNF antagonists can be valuable for patients in need and therefore appropriate for reimbursement by national health systems and third-party payors.
KeywordsRheumatoid Arthritis Infliximab Etanercept Adalimumab Swell Joint Count
>We are paid consultants of Abbott Laboratories. In addition, we wish to thank Michael Nissen of the Biomedical Publishing Group of Abbott Laboratories for his editorial contributions to this article.
- 4.O’Dell J. Conventional DMARD options for patients with a sub optimal response to methotrexate. Rheumatology 2001; 28: 21–6Google Scholar
- 13.National Institute for Clinical Excellence. Technology Appraisal Guidance—No. 36: guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. 2002 MarGoogle Scholar
- 20.Breedveld FC, Rau R, van Riel PLC. Sustained efficacy over 5 years with adalimumab (HUMIRA®) in patients with active rheumatoid arthritis [abstract]. Arthritis Rheum 2003; 48(9): S118Google Scholar
- 21.van de Putte LBA, Rau R, Burmester GR. Sustained 5-year efficacy of adalimumab (HUMIRA®) monotherapy in DMARD-refractory rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2003; 48(9): S314Google Scholar
- 23.Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes with adalimumab (a human anti-TNF monoclonal antibody) in the treatment of patients with active rheumatoid arthritis on concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. In pressGoogle Scholar
- 24.Weinblatt ME, Keystone EC, Furst DE, et al. The ARMADA Trial: sustained improvement and tolerability in long-term follow-up of patients treated with adalimumab (HUMIRA®) [poster presentation]. American College of Rheumatology 2003 annual conference 2003 Oct 26, Orlando (FL)Google Scholar
- 25.Van de Putte LBA, Atkins C, Malaise M, et al. Adalimumab (D2E7) monotherapy in the treatment of patients with severely active rheumatoid arthritis [abstract]. Arthritis Rheum 2002; 46 Suppl.: S205Google Scholar
- 26.Keystone EC, Kavanaugh A, Sharp J. Sustained radiographie inhibition with adalimumab (HUMIRA®) over 2 years in patients with long-standing rheumatoid arthritis (RA) [poster presentation]. American College of Rheumatology 2003 annual conference 2003 Oct 26, Orlando (FL)Google Scholar
- 27.Pincus T, Brook RH, Callahan LF, et al. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 1994; 120: 25–4Google Scholar
- 30.FDA Arthritis Advisory Committee Reports [online]. 2003 Mar 4. Available from URL: http://www.fda.gov [Accessed 2003 Dec 23]
- 31.Bansback NJ, Brennan A, Ghatekar O, et al. The cost effectiveness of adalimumab (HUMIRA®) in patients with rheumatoid arthritis (RA): a Swedish analysis [poster presentation]. American College of Rheumatology 2003 annual conference 2003 Oct 27, Orlando (FL)Google Scholar
- 32.Bansback NJ, Brennan A, Sengupta N, et al. Cost effectiveness of adalimumab (HUMIRA®) in the treatment of patients with moderate to severe rheumatoid arthritis (RA) [poster presentation]. American College of Rheumatology 2003 annual conference 2003 Oct 25, Orlando (FL)Google Scholar